Prestoflam LD

Quick links to important sections

Prestoflam LD

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prestoflam LD

What is Prestoflam LD? Overview

Property Description
Active ingredients Clonixin, Diclofenac
Form Oral preparations (e.g., tablets)
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Pain relief and reduction of inflammation
Origin Synthetic compound

Defining Prestoflam LD: A Combination NSAID

Prestoflam LD is defined as a combination pharmaceutical product classified within the therapeutic category of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), designed for comprehensive analgesic and anti-inflammatory relief. This medicine is characterized by its synthetic origin, with its formulation primarily targeting the pathways responsible for pain and swelling. As a combination drug, it leverages the properties of two distinct active agents simultaneously. It is generally formulated as oral preparations, such as tablets or capsules, for administration via the oral route.

The Dual-Mechanism Composition: Clonixin and Diclofenac

The pharmacological core of Prestoflam LD is the strategic combination of two distinct active ingredients: Clonixin and Diclofenac. This pairing creates a dual-mechanism agent aimed at providing comprehensive therapeutic effects. Diclofenac is a widely recognized NSAID identified as a phenylacetic acid derivative known for its significant anti-inflammatory action. Clonixin, an anthranilic acid derivative, is specifically included for its established analgesic strength. This combination is often utilized where both pronounced pain and moderate inflammation are present, such as in musculoskeletal discomfort.

General Purpose: Reducing Pain and Easing Inflammation

The overall purpose of this medication is to reduce discomfort and ease the physical signs of inflammation at the affected site. By pairing a component with robust anti-inflammatory capability and one with dominant pain relief, the drug effectively intervenes in the biological cycle that causes both pain and inflammation. This systemic action allows the drug to provide general symptomatic relief, contributing to improved comfort and functionality across various conditions characterized by both pain and inflammation.

What side effects are possible with Prestoflam LD?

Possible side effects and safety information

This section outlines the officially documented adverse effects and safety characteristics of this combination medication, based on regulatory classifications established by government health authorities.


Adverse Reaction Classification

Adverse reactions are classified by frequency and grouped according to the body system affected (System-Organ-Class or SOC). Common side effects, defined as occurring in 1% or more of patients in clinical data, typically involve the Gastrointestinal disorders and Nervous system disorders. These may include effects such as headache, dizziness, nausea, vomiting, dyspepsia, and abdominal pain.

Rare and Very Rare classifications are reserved for less frequent but clinically serious adverse reactions, which can affect the body's systems, including the Hepatobiliary disorders (liver) and Renal and urinary disorders (kidneys).


Serious Adverse Reactions and Safety Constraints

Official regulatory documents cite potentially serious risks associated with this type of Non-Steroidal Anti-Inflammatory Drug (NSAID) combination. These include the risk of Gastrointestinal Bleeding, Ulceration, and Perforation, which can occur without warning. There is also a documented risk of Serious Cardiovascular Thrombotic Events such as myocardial infarction and stroke.

Safety notes tied to exposure indicate that the risk of Cardiovascular Thrombotic Events may increase with the duration of use. Furthermore, regulatory labels define restrictions: the medicine is Contraindicated in individuals with established severe heart failure (NYHA Class II-IV), severe renal failure, severe hepatic impairment, or active gastrointestinal ulceration. Older adults are noted as a population with an increased risk of serious GI and cardiovascular events.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation defines the profile of Prestoflam LD overdose by listing specific, documented manifestations that require immediate attention. An overdose of this NSAID combination may initially present with Gastrointestinal symptoms such as nausea, vomiting (potentially bloody), and stomach pain, alongside Central Nervous System effects like dizziness, headache, confusion, and tinnitus.


Documented Severe Outcomes and Required Actions

The regulatory framework establishes the high potential for serious or life-threatening outcomes that necessitate urgent intervention. These severe manifestations documented in official labeling include Gastrointestinal bleeding or perforation, acute renal failure (kidney damage), seizures, and shock. This severity dictates the explicit instruction to seek emergency medical help right away or contact emergency services immediately if symptoms such as chest pain or breathing difficulty occur. Hospital monitoring and continuous observation of vital signs and renal function are required in cases of large ingestion or symptomatic presentation.


Management and Antidote Information

Regulatory documents confirm that no specific antidote is known for this NSAID class overdose. Consequently, management is officially described as being symptomatic and supportive, which may involve procedures such as the administration of activated charcoal or other supportive measures. Official labeling notes that elderly patients and those with existing renal or hepatic impairment face a greater risk for severe adverse outcomes following an overdose.

Therapeutic Uses of Prestoflam LD

Prestoflam LD contains the active ingredient diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) which is commonly used to help with symptoms related to inflammatory or irritative states. This medication is applied across domains where additional symptomatic support is needed, particularly in contexts involving heightened systemic burden, and helps ease the overall symptom load. It provides support that helps ease the overall symptom burden associated with a variety of conditions.


This medication may be part of symptomatic management for conditions characterized by periods of heightened symptoms, such as different forms of arthritis, including osteoarthritis and rheumatoid arthritis, as well as symptoms related to physical discomfort like back pain or sprains. It contributes to improved comfort during episodes associated with acute or episodic changes, such as mild-to-moderate acute pain or primary dysmenorrhea (menstrual cramps). The treatment supports general well-being during symptomatic phases.

“This approach may assist with maintaining functional stability when symptoms interfere with routine activities.”

Quick Fact: Addresses Symptoms of Physical Discomfort

Eligibility and Restrictions for Use

Eligibility and Contraindications for Prestoflam LD

Use of Prestoflam LD is strictly defined by regulatory guidelines for systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Only adult patients without listed contraindications are generally eligible for use.

Population Status Regulatory Rule (Non-Eligibility)
Absolute Contraindication Use is prohibited for patients with known NSAID hypersensitivity (including aspirin-sensitive asthma), active GI ulceration or bleeding, or a history of recurrent haemorrhage. It is also contraindicated in severe hepatic, renal, or heart failure (NYHA II-IV), established ischemic heart disease, and during the third trimester of pregnancy (after 30 weeks).
Restricted/Conditional Use Use requires caution and close monitoring for patients with mild to moderate renal or hepatic impairment, those with uncontrolled hypertension, or pre-existing Crohn’s disease or Ulcerative Colitis. Geriatric patients (65+) should receive the lowest effective dose.
Age Eligibility Use is not recommended in children and adolescents under 18 years of age as safety and efficacy for systemic oral formulations have not been established.

Use during the first and second trimesters of pregnancy is restricted and should be avoided unless medically essential. The official labeling generally advises against use in women who are breastfeeding.

What should I know about interactions with other medicines?

Prestoflam LD contains two Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), making its interaction profile highly structured by the established warnings of the NSAID class, as defined by government regulatory documents.

Official Interaction Statements

Classification Interacting Agents / Conditions Documented Regulatory Outcome
Contraindicated Perioperative CABG surgery Strictly prohibited for use in this setting.
Contraindicated Aspirin or other NSAIDs Prohibited in patients with a history of hypersensitivity reactions to those agents.
Risk Reinforcement Anticoagulants (e.g., Warfarin) Co-administration increases the risk of bleeding and hemorrhage.
Efficacy Reduction ACE Inhibitors, ARBs, and Diuretics May diminish the antihypertensive or natriuretic effect of these medicines.
Exposure Alteration Voriconazole (CYP2C9 inhibitor) Documented to increase the plasma concentration and exposure (AUC/Cmax) of the diclofenac component.
Clearance Reduction Lithium and Methotrexate Diclofenac reduces the renal clearance of these drugs, which can increase their serum concentrations and risk of toxicity.

Substance and Timing Constraints

  • Alcohol: Consumption may officially increase the risk of serious gastrointestinal adverse events, including bleeding and perforation.
  • Pemetrexed: For patients with renal impairment, short-half-life NSAIDs like diclofenac should be avoided for a defined period of two days before, the day of, and two days following pemetrexed administration.
  • Population Note: The interaction with ACE Inhibitors/ARBs carries an increased risk of renal function deterioration in the elderly, volume depleted, or renally impaired population.

Mechanism of Action

The mechanism of action for Prestoflam LD is defined by the complementary inhibition of the Cyclooxygenase ( COX-1 and COX-2) enzymes by its active components. This molecular interaction interrupts the Arachidonic Acid Cascade , which restricts the biosynthesis of pro-inflammatory eicosanoid mediators, specifically Prostaglandins ( PGE2). Diclofenac's PGE2 suppression influences the activation threshold of peripheral nociceptive nerve endings. Clonixin contributes by modulating non-COX targets, potentially including inward calcium channels, which affects the electrical excitability of these pain-sensing neurons. The combination results in enhanced suppression of nociceptive signaling compared to a single-component action. The resultant systemic physiological modulation includes the suppression of nociceptive signal transmission and the modulation of vascular permeability and vasodilation at the affected site via decreased Prostaglandin levels. These changes modulate localized physiological responses stemming from excessive mediator activity.

Dosage and Administration Information

Prestoflam LD, a combination Non-Steroidal Anti-Inflammatory Drug (NSAID) containing diclofenac and clonixin, is authorized for administration via two primary routes: oral (tablets/capsules) and parenteral (solution for injection).

The overarching principle governing its use requires administering the lowest effective dose for the shortest possible duration (L.E.D./S.P.D.). This administration strategy is intended to ensure systemic relief while strictly limiting exposure time.

Administration Patterns

Oral forms are typically taken in divided doses daily. Specific instructions recommend taking the tablets with or immediately after food to ease potential gastrointestinal discomfort. Furthermore, forms with modified release characteristics must be swallowed whole and cannot be crushed, split, or chewed, a procedural constraint critical for ensuring the correct release of the active ingredients.

The injectable, or parenteral, route is reserved exclusively for the short-term management of acute, severe episodes and is generally restricted to a maximum duration of two days. The solution for intravenous infusion requires dilution and buffering before administration and must not be given as a rapid bolus injection.

In specific patient populations, such as older adults or those with impaired hepatic or renal function, the official instruction is to initiate treatment using the lowest dosage due to altered physiological response patterns.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prestoflam LD

The research base for Prestoflam LD, a combination Non-Steroidal Anti-Inflammatory Drug (NSAID), was studied for conditions characterized by outcomes related to physical discomfort and inflammatory or irritative states. The research provides context for outcomes related to physical discomfort and how symptoms were measured in specific research scenarios.

Evidence for Use in Chronic Joint Pain (Osteoarthritis and Rheumatoid Arthritis)

This section will summarize the structure of clinical research, including Randomized Controlled Trials and high-level reviews, that detail the types of clinical research that explored outcomes related to physical discomfort and daily functioning or activity level in chronic joint conditions.

The clinical research framework for chronic conditions involves Randomized Controlled Trials (RCTs) and Systematic Reviews that monitor responses over defined time intervals. These studies monitored outcomes linked to inflammatory or irritative states and were applied in studies examining patient-reported experiences associated with chronic joint pain, such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA). Findings describe patterns observed in the studies related to changes measured during the study period in outcomes related to physical discomfort and outcomes reflecting daily functioning.

However, long-term effects are not fully established. Follow-up durations were often limited, meaning there is limited information for long-term outcomes regarding the durability of the reported effects beyond the trial periods.

Evidence for Use in Acute Pain and Musculoskeletal Sprains

This part will outline the short-term, placebo-controlled research designs that research examined in the context of outcomes describing episodic or acute changes.

Research exploring short-term symptom changes for conditions characterized by acute or disruptive episodes was primarily conducted using short-term, placebo-controlled clinical trials. Research examined outcomes related to physical discomfort, including the time to onset of observed effects and the measurement of rescue analgesic medication. Because these studies were conducted during periods of increased symptom activity, follow-up durations were limited, often to a single dose or a few days. Data show patterns related to the measurement of time to observed effects and symptom intensity or variability.

Gaps in Research and Areas of Uncertainty

This concluding section will synthesize the major limitations noted in the research landscape, covering areas such as the variability in trial findings and remaining questions.

Comparative evidence is lacking for the specific combination versus monotherapy over extended periods. Data for certain groups, such as children, pregnant women, or older adults with significant comorbidities, may be insufficient or narrowly focused. Furthermore, findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Prestoflam LD (FAQ)

Q: What is the difference between Prestoflam LD and other common anti-inflammatory drugs?

A: Official product information describes Prestoflam LD as a combination medicine with a dual mechanism of action. While one component restricts the creation of inflammatory prostaglandins (a common NSAID action), the other component, clonixin, is documented to modulate non-COX targets, which may influence pain-sensing nerves. This combined action is the basis for its distinction from single-agent NSAIDs.

Q: What is the most common reason people are prescribed Prestoflam LD?

A: The active components in Prestoflam LD are officially indicated for providing relief from the signs and symptoms associated with pain, swelling, and stiffness. This generally includes discomfort related to chronic conditions like rheumatoid arthritis and osteoarthritis, as well as acute (short-term) painful episodes.

Q: How quickly should I expect Prestoflam LD to start working?

A: Clinical studies have examined the effect of the active ingredients on acute pain. For rapid-onset conditions, the onset of pain relief can begin to be observed relatively quickly after administration. However, if the medicine is prescribed for chronic inflammatory conditions, official information indicates that the full therapeutic benefit may not be observed until after several days or up to two weeks.

Q: Is Prestoflam LD known to cause drowsiness?

A: Regulatory labels for the active ingredients list drowsiness and somnolence (sleepiness) as possible adverse effects. Official guidance indicates that due to possible nervous system effects, patients should be aware the medicine may impair the ability to operate complex machinery or drive.

Q: Are there any food restrictions when taking Prestoflam LD?

A: Regulatory documents note that the oral form is typically administered with or immediately following food to minimize potential stomach upset. Official information strongly cautions against consuming alcohol while using this medicine, as this can increase the risk of serious gastrointestinal side effects, including bleeding.

Q: How does Prestoflam LD affect blood pressure?

A: According to official warnings, medications in this class can cause new onset high blood pressure (hypertension) or worsen existing high blood pressure. Official documents advise that blood pressure monitoring is necessary when this medication is administered.

Q: Does Prestoflam LD contain any steroids?

A: No. Prestoflam LD is explicitly classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This means its active agents, Diclofenac and Clonixin, are synthetic compounds that do not contain corticosteroids.

Q: Is it normal to feel a bit light-headed after starting Prestoflam LD?

A: Official product information lists dizziness as a common side effect of the active ingredients. This feeling may be experienced as light-headedness. If this symptom is severe or persistent, patients are advised to seek guidance from a healthcare professional.

Q: Does the 'LD' formulation mean fewer side effects compared to the standard version?

A: The official administration principle for this entire class of medication is the Lowest Effective Dose for the Shortest Possible Duration (L.E.D./S.P.D.). This strategy is mandated by regulatory bodies to minimize potential systemic exposure and the risk associated with serious adverse events, particularly cardiovascular and gastrointestinal risks.

Q: Why is official monitoring sometimes recommended for patients using Prestoflam LD?

A: Regulatory documents indicate that patients at high risk of complications—such as older adults or those with pre-existing kidney or liver impairment—may require monitoring. Official guidance indicates that monitoring may include checks on kidney and liver function during treatment.

Q: How long does the effect of a single dose of Prestoflam LD typically last?

A: The pharmacokinetics (how the body handles the drug) of one of the main active components, Diclofenac, is characterized by a short half-life of approximately two hours. This pharmacological profile often correlates with dosing schedules that require the medicine to be administered multiple times per day, as outlined in official guidelines.

Q: Can Prestoflam LD affect sleep patterns?

A: Yes, official adverse reaction profiles for the active ingredients include reports of sleep disorders, insomnia (difficulty sleeping), and abnormalities in dreaming. These are categorized under the Nervous System and Psychiatric disorders.

Q: Are there any specific vitamins or supplements that are known to interact with Prestoflam LD?

A: While regulatory documents specifically list interactions with many prescription drugs, they generally instruct patients to inform their healthcare providers about all concomitant products. This includes vitamins, herbal remedies, and supplements, due to a risk that they may increase adverse events, such as bleeding.

Q: Is it safe to use Prestoflam LD if I am already taking an anti-depressant?

A: Official information warns that combining this type of anti-inflammatory medicine with certain types of antidepressants, such as SSRIs or SNRIs, may increase the risk of serious gastrointestinal bleeding. Official labeling indicates that monitoring by a healthcare professional is important when these medicines are used together.

Q: What should be included in a doctor's discussion before starting Prestoflam LD?

A: According to the Patient Counseling Information sections of the official labels, a discussion with a healthcare provider should cover all current and past medical conditions. It is essential to review any history of heart, kidney, or liver issues, as well as all other medicines being taken, to facilitate assessment of potential individual risks.

Q: Does Prestoflam LD have any effect on mental clarity or focus?

A: Reported adverse reactions for the active components include psychiatric and nervous system effects such as confusion and depression. Official regulatory warnings advise patients to be aware that the medicine may affect mental processes and could impair the ability to perform tasks requiring focus.

Q: Are skin rashes a possible side effect of Prestoflam LD?

A: Yes, official adverse reaction profiles list skin rash as a possible side effect. Furthermore, the regulatory labels carry serious warnings regarding rare but severe skin reactions, such as Stevens-Johnson Syndrome (SJS), which require immediate attention.

Q: Can Prestoflam LD cause changes in appetite or weight?

A: Regulatory labels for the active components list changes in appetite (anorexia) and weight changes as occasionally reported adverse experiences related to the metabolic and nutritional system.

Q: Are there known interactions between Prestoflam LD and herbal teas or remedies?

A: Official regulatory warnings emphasize that patients should discuss the use of all herbal remedies and teas with their healthcare provider. This is because many herbs, such as ginkgo biloba, can increase the risk of bleeding when taken alongside this type of anti-inflammatory medicine.

Q: Is Prestoflam LD described as habit-forming or addictive?

A: No. According to regulatory classifications, this medicine belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class. This class of medication is not typically associated with dependence, abuse, or habit-forming potential.

Q: Can Prestoflam LD cause dry mouth or throat?

A: Yes, official adverse reaction profiles for the active components include dry mouth as an occasionally reported side effect affecting the digestive system.

Q: Is it normal to experience vivid dreams while taking Prestoflam LD?

A: Vivid dreams or other dream abnormalities are listed in the adverse reaction profile for the active components under the Nervous System and Psychiatric disorder classifications.

Q: What should I do if I think Prestoflam LD is not working for me?

A: Official guidance advises patients not to alter the dose or duration of their use without instruction. If the medication does not appear to be providing sufficient relief, official guidance recommends seeking guidance from a healthcare professional to review the treatment plan.

Q: Can Prestoflam LD be used to treat migraines?

A: The active ingredient, Diclofenac, has certain formulations that are specifically indicated by regulatory agencies for the acute treatment of migraine attacks in adults. However, the approved indications for any specific combination product may vary by region.

Q: Does Prestoflam LD carry a specific warning in regulatory labeling, like a Black Box Warning?

A: Yes. As a member of the NSAID drug class, the active components carry a Boxed Warning on regulatory labels. This warning highlights the risks of serious, potentially fatal, cardiovascular thrombotic events (such as heart attack and stroke) and serious gastrointestinal adverse events (such as bleeding and ulceration).

How should Prestoflam LD be stored and disposed of?

How to Store and Dispose of Prestoflam LD?

The official guidelines for storing and disposing of this medicine are based on regulatory documentation to maintain product stability and ensure environmental safety.

Requirement Area Official Labeling Statement
Storage Conditions Store the product in a cool place (generally not exceeding 25 C), kept dry, and protected from light. Do not expose the medicine to heat or freezing.
Container Security Keep the product in its original receptacle with the container tightly closed.
Child Protection Mandatory: The medicine must be kept out of the reach of children and stored locked up.
Disposal Instructions Contents and container must be disposed of in accordance with local and national regulations. Avoid release to the environment; the product must not be allowed to enter sewers, surface, or ground water.

These official rules strictly define the storage environment and disposal procedures, prohibiting the disposal of the product via household drains or wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prestoflam LD found in:

A-Z Index: